Some of the contents of this website cannot be promoted in the USA (including its territories and possessions) for regulatory reasons.

Please choose your country/geographic area:

International

USA **including its territories and possessions

Genitourinary Syndrome of Menopause, Stress Urinary Incontinence

Long-term Effects of Vaginal Erbium Laser in the Treatment of Genitourinary Syndrome of Menopause

Authors: M. Gambacciani, M. Levancini, E. Russo, L. Vacca, T. Simoncini and M. Cervigni

Published in Climacteric. 2018;21(2):148-152





1. TWO-YEAR FOLLOW UP OF PATIENTS

First longitudinal study on the use of minimally invasive Er:YAG technology for the treatment of genitourinary syndrome of menopause (GSM), showing long-term efficacy of RenovaLase®.

2. LARGE GROUP OF TREATED PATIENTS

205 postmenopausal women received three laser sessions of RenovaLase® at 30-day intervals. Study assessment was performed throughout the 24-month follow-up period and included the subjective visual analogue scale (VAS) and the objective vaginal health index score (VHIS). Furthermore, postmenopausal women suffering from stress urinary incontinence symptoms were evaluated with the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF).

3. BETTER RESULTS COMPARED TO LOCAL TREATMENT

Non-ablative Er:YAG laser treatment induced a statistically significant (p <0.01) decrease in VAS for vaginal dryness and dyspareunia, and VHIS was significantly increased (p <0.01) up to the 12th month after the final laser treatment. Values reported after 18 and 24 months returned to the baseline level. Furthermore, 144 women suffering from mild to moderate SUI also showed improvement in urine leakage. No major adverse events were reported.

4. STRONG PROOF OF EFFICACY AND SAFETY OF THE RENOVALASE® TREATMENT

The efficacy of non-ablative Er:YAG laser treatment has been demonstrated by several clinical studies, but data on long-term effects was lacking to fully support it. This longitudinal study therefore fills an important gap in the story of non-invasive treatments for GSM.

Read article

Back

Find More Knowledge On:

Join Us on Social Networks

Download Fotona Mobile Application

All information published in this website is of general nature and only has an informative purpose. Under no circumstances can it replace any treatment or therapy prescribed by a physician or other healthcare professional. Any information on medical procedures and treatments in this website are intended for informative purposes only and do not provide the knowledge required for their application.

All Fotona medical lasers are CE marked and cleared for sale in the EU. For countries where specific national approvals or clearances are required (for example by the FDA in the United States), some of the products and/or applications may not have been cleared yet. Similarly, local patents may limit usage for certain technologies and applications. Please check with Fotona, your local Fotona distributor or your national regulatory body to find out whether a specific product or application is available for sale and use in your country.

Fotona 2023 ©